Viyash Scientific
Viyash Scientific Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: order book.
The short version
Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration. Company expects sustainable double-digit revenue growth, targeting around 15%-17% growth over the next 2 years. - Majority of new product revenue is expected from 2029 onwards due to product gestation and patent expiries. - The 2032 aspiration includes reaching revenues of $150-200 million in companion animal segment, supported by organic growth and inorganic acquisitions. - EBITDA margins targeted around 20%-22%, with continuous margin expansion expected. - Profit after tax doubled year-on-year in Q1 FY’27, indicating strong profitability momentum. - API and Animal Health segments to grow mid-teens to 20%+ over near term. - Acquisition synergy and market expansion in Europe to contribute to growth from 2029 onwards. - CAPEX planned in range of Rs.
From Viyash Scientific's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration.
- Significant growth anticipated post-2029, driven by patent expiries on Animal Health (2027-2033) and Human API products (post-2030).
- Majority of new product revenues expected from 2029 onwards, considering 3-5 years gestation for product development and regulatory approvals.
- Animal Health segment growing faster, currently about one-third of API revenue, with focus on formulations and expanding manufacturing capacity.
- European acquisition (BioForLife) to contribute substantially after 2-3 years (post-2028) with estimated €150-200 million revenue by 2032.
- Emerging markets (Turkey, Brazil, Mexico) showing strong volume growth (~25%), expected to sustain momentum.
- Human API portfolio targets 10%-15% market share per product, focusing on first-to-file launches and sustainability.
- Overall, confident in achieving an 18% CAGR up to 2032, with balanced organic and inorganic growth strategies.
Profitability & Margins
See what Viyash Scientific said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for FY’27 is around Rs. 250 crores to Rs. 300 crores.
- Current capital allocation is balanced; majority business (90%) is mature and requires limited new investment.
- New investments focus on R&D, manufacturing expansion, and strategic areas like high potent API and formulation capabilities.
- Manufacturing plant for companion animal products being prepared with expected readiness by January-February following equipment orders placed and design finalization.
- Company plans selective inorganic growth via acquisitions aligned with strategic direction (Animal Health, CDMO, complex molecules).
- Interest cost restructuring underway to optimize financing costs.
- M&A activity expected to accelerate growth; minority interests in US and Spain anticipated to be acquired within next 1-2 years.
- Overall, capital allocation is disciplined with focus on compliance, sustainable growth, and integrating new capabilities.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Viyash Scientific said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Viyash Scientific — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹920 Cr, net profit ₹66 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Viyash Scientific Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Viyash Scientific Q1 FY27 results?
Expect steady double-digit revenue growth with 15%-17% growth in next 2 years (up to 2028) before acceleration. Company expects sustainable double-digit revenue growth, targeting around 15%-17% growth over the next 2 years. - Majority of new product revenue is expected from 2029 onwards due to product gestation and patent expiries. - The 2032 aspiration includes reaching revenues of $150-200 million in companion animal segment, supported by organic growth and inorganic acquisitions. - EBITDA margins targeted around 20%-22%, with continuous margin expansion expected. - Profit after tax doubled year-on-year in Q1 FY’27, indicating strong profitability momentum. - API and Animal Health segments to grow mid-teens to 20%+ over near term. - Acquisition synergy and market expansion in Europe to contribute to growth from 2029 onwards. - CAPEX planned in range of Rs.
What is Viyash Scientific share price analysis?
Viyash Scientific currently shows a below-average growth signal. The stock trades at a P/E of 54.8 with a market cap of ₹12,139 Cr. Investors should review the full earnings analysis for detailed insights.
Is Viyash Scientific planning capital expenditure?
Capex guidance for FY’27 is around Rs.
Keep Viyash Scientific on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.